JP2015522522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522522A5 JP2015522522A5 JP2015503431A JP2015503431A JP2015522522A5 JP 2015522522 A5 JP2015522522 A5 JP 2015522522A5 JP 2015503431 A JP2015503431 A JP 2015503431A JP 2015503431 A JP2015503431 A JP 2015503431A JP 2015522522 A5 JP2015522522 A5 JP 2015522522A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- prevent
- relapse
- nicotine
- nicotine antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drugs Drugs 0.000 claims 7
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 5
- 229960002715 Nicotine Drugs 0.000 claims 5
- 230000003042 antagnostic Effects 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 229930015196 nicotine Natural products 0.000 claims 5
- 230000000638 stimulation Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000003367 nicotinic antagonist Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (3)
- 薬物再燃を防止する治療に使用されるα３β４ニコチン拮抗薬であって、
薬物使用初期の後に哺乳動物に投与され、
薬物使用再燃を防止する、
α３β４ニコチン拮抗薬。 - 刺激による誘発を原因とする薬物使用再燃を防止する治療に使用されるα３β４ニコチン拮抗薬であって、
薬物使用初期の後に哺乳動物に投与され、
刺激による誘発中に薬物使用再燃を防止する、
α３β４ニコチン拮抗薬。 - 薬物使用再燃を防止する治療に使用されるα３β４ニコチン拮抗薬であって、
刺激による誘発中に薬物使用再燃を防止する、
α３β４ニコチン拮抗薬。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615953P | 2012-03-27 | 2012-03-27 | |
| US61/615,953 | 2012-03-27 | ||
| PCT/US2013/033703 WO2013148572A1 (en) | 2012-03-27 | 2013-03-25 | Blocking of cue-induced drug reinstatement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015522522A JP2015522522A (ja) | 2015-08-06 |
| JP2015522522A5 true JP2015522522A5 (ja) | 2016-05-19 |
Family
ID=49261147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503431A Pending JP2015522522A (ja) | 2012-03-27 | 2013-03-25 | 刺激に誘発される薬物再発の阻止 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150051192A1 (ja) |
| EP (1) | EP2830601A4 (ja) |
| JP (1) | JP2015522522A (ja) |
| AU (1) | AU2013239995A1 (ja) |
| CA (1) | CA2908240A1 (ja) |
| WO (1) | WO2013148572A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394294B2 (en) | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
| JP6049615B2 (ja) | 2010-07-23 | 2016-12-21 | デマークス・インコーポレイテッドＤｅｍｅｒｘ，Ｉｎｃ． | ノリボガイン組成物 |
| EP2481740B1 (en) | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| US9617274B1 (en) | 2011-08-26 | 2017-04-11 | Demerx, Inc. | Synthetic noribogaine |
| US8877921B2 (en) | 2012-01-25 | 2014-11-04 | Demerx, Inc. | Synthetic voacangine |
| JP2016508979A (ja) * | 2012-12-20 | 2016-03-24 | デメレックス， インコーポレイテッド | 置換ノルイボガイン |
| CA2983727A1 (en) * | 2014-04-21 | 2015-10-29 | Demerx, Inc. | N-substituted noribogaine prodrugs |
| JP2022552162A (ja) * | 2019-10-01 | 2022-12-15 | マインド メディシン， インコーポレイテッド | 物質使用障害の処置のための１８－ｍｃ |
| WO2023278108A1 (en) * | 2021-06-29 | 2023-01-05 | Mind Medicine, Inc. | 18-mc for treating obesity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL123220A0 (en) * | 1995-08-08 | 1998-09-24 | Albany Medical College | Ibogamine congeners |
| US6780871B2 (en) * | 2001-01-29 | 2004-08-24 | Albany Medical College | Methods and compositions for treating addiction disorders |
| US20030199439A1 (en) * | 2002-04-22 | 2003-10-23 | Simon David Lew | Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics |
| WO2006017861A2 (en) * | 2004-08-13 | 2006-02-16 | Omeros Corporation | Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists |
| EP2086541A4 (en) * | 2006-10-09 | 2011-06-22 | Glaxosmithkline Llc | COMPOSITIONS FOR REDUCING NICOTINE WEANING SYMPTOMS AND / OR TOBACCO USE |
| WO2008087123A2 (en) * | 2007-01-16 | 2008-07-24 | Solvay Pharmaceuticals B.V. | Use of 5-ht6 antagonists to prevent relapse into addiction |
| KR101767273B1 (ko) * | 2009-03-11 | 2017-08-10 | 오메로스 코포레이션 | 중독의 예방 및 치료용 조성물 및 방법 |
| US8785472B2 (en) * | 2010-05-11 | 2014-07-22 | National Cheng Kung University | Use of dextromethorphan in treating addictive behavior or bipolar disorder |
-
2013
- 2013-03-25 WO PCT/US2013/033703 patent/WO2013148572A1/en active Application Filing
- 2013-03-25 JP JP2015503431A patent/JP2015522522A/ja active Pending
- 2013-03-25 US US14/387,339 patent/US20150051192A1/en not_active Abandoned
- 2013-03-25 AU AU2013239995A patent/AU2013239995A1/en not_active Abandoned
- 2013-03-25 CA CA2908240A patent/CA2908240A1/en not_active Abandoned
- 2013-03-25 EP EP13768831.3A patent/EP2830601A4/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522522A5 (ja) | ||
| CY1123937T1 (el) | Σκευασμα ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης | |
| CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| JP2016515522A5 (ja) | ||
| EP2968306A4 (en) | ADMINISTRATION OF NICOTINAMIDE MONONUCLEOTIDE IN THE TREATMENT OF DISEASES | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| MX2021015234A (es) | Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano. | |
| JP2015503422A5 (ja) | ||
| WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
| MX2015017201A (es) | Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga. | |
| JP2017514871A5 (ja) | ||
| EP3141603A4 (en) | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective | |
| DK2819726T3 (da) | Medikamentadministrationsanordning med fast dosis | |
| HK1245115A1 (zh) | 口腔奧曲肽與其他治療劑聯合應用 | |
| BR112017000556A2 (pt) | terapia de combinação para câncer | |
| EA032938B1 (ru) | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения | |
| MX2016008429A (es) | Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria. | |
| JP2015535291A5 (ja) | ||
| IL245738A0 (en) | Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases | |
| EP3318879A4 (en) | Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag | |
| EA201690974A1 (ru) | Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника | |
| MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| EP2959906A4 (en) | ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE | |
| EP2959908A4 (en) | ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES | |
| EP2959905A4 (en) | ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES |